Taken together, the above animal and human studies indicate that SFN-medicated activation of Nrf2 reduces EC activation at atherosusceptible sites, regulates migration and proliferation of VSMC, decreases the expression of inflammatory factors, prevents HFD-induced obesity, and has antithrombic effect. This evidence concerns the gene NFE2L2 and Obesity.